Lupus News and Research

Latest Lupus News and Research

New approach in treating multiple sclerosis

In his article, "Pathoetiology of multiple sclerosis: are we barking up the wrong tree?", Peter K. Stys of the Hotchkiss Brain Institute, University of Calgary, argues that while the majority of the medical research community currently approaches MS as an autoimmune disease (much like Lupus and Rheumatoid Arthritis), for which the trigger is the immune system attacking a particular part of the nervous system, the features of the disease are equally well explained by approaching MS as a neurodegenerative disease (such as Parkinson's and Alzheimer's), which is followed by an immune reaction to damage.

5 Jun 2013

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.

4 Jun 2013

Lupus Foundation of America announces Career Development Award and new summer fellowships

The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award.

3 Jun 2013

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance.

28 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

World Lupus Day: Lupus organizations to rally together to raise awareness of lupus

The Lupus Foundation of America and lupus organizations around the globe are rallying together on May 10, World Lupus Day, to urge action and raise awareness of lupus, a mysterious and devastating disease that ravages different parts of the body.

10 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Researchers from the Royal College of Surgeons in Ireland have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus could potentially benefit Irish patients who suffer from the condition.

8 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say.

30 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune system attacks the body’s own tissues, especially the membranes that line the joints. As a result, fluid builds up in the joints, causing pain and systemic inflammation, leading to joint destruction if untreated.

From Quest Diagnostics 23 Apr 2013

Researchers urge doctors to consider Lyme disease as cause when presented with skin lesions

When a person contracts Lyme disease, quick diagnosis and treatment are essential to avoiding long term complications. But the diagnostic process may be delayed if a physician does not recognize a skin rash caused by Lyme disease because it does not have the bull's-eye appearance that is best known to physicians and the public.

23 Apr 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

A researcher at The Feinstein Institute for Medical Research has discovered additional mechanical properties of articular cartilage, a protective cartilage on the ends of bones that wears down over time, resulting in the development of osteoarthritis.

20 Apr 2013

Telemedicine house calls for Parkinson’s patients: an interview with Dr Ray Dorsey, Johns Hopkins University

Access to neurological care for Parkinson disease is currently limited by distance, disability, and the distribution of doctors.

18 Apr 2013

AARDA creates new multi-media public service campaign for AD patients

In response to a recent study that found roughly one-third of prescriptions for autoimmune disease patients go unfilled and a high level of physician mistrust exists among AD patients, the American Autoimmune Related Diseases Association, Inc. has created a new multi-media public service campaign with tools designed to help patients make informed decisions about newly-prescribed therapies and treatments.

17 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Lupus News and Research

Latest Lupus News and Research

New approach in treating multiple sclerosis

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Lupus Foundation of America announces Career Development Award and new summer fellowships

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

World Lupus Day: Lupus organizations to rally together to raise awareness of lupus

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Rigel reports net loss of $25.6 million in first quarter 2013

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

Opsona raises €33M in oversubscribed financing round

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Researchers urge doctors to consider Lyme disease as cause when presented with skin lesions

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

Telemedicine house calls for Parkinson’s patients: an interview with Dr Ray Dorsey, Johns Hopkins University

AARDA creates new multi-media public service campaign for AD patients

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Lupus News and Research

Latest Lupus News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in